ReviewCurrent transplantation reports2021
Donor-Derived Cell-Free DNA for Acute Rejection Monitoring in Heart and Lung Transplantation.
Review in Current transplantation reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Graft rejection across solid organ transplants: mechanisms, monitoring, and immunosuppressive therapeutics.Frontiers in surgery · 2026Pooled it
- Artificial intelligence and machine learning in heart and lung transplantation.EClinicalMedicine · 2026Review
- Donor-derived cell-free DNA as a noninvasive biomarker for diagnosis and monitoring of acute rejection after liver transplantation.Frontiers in immunology · 2026Article
- A Prospective Pilot Study to Investigate Whether Donor-Derived Cell-Free DNA Can Be Used as a Biomarker of Recurrent IgA Nephropathy Post-Kidney Transplantation.International journal of immunogenetics · 2025Article
- Unique association of extreme elevation of cell free DNA and histologic patterns of intra-alveolar injury among lung transplant recipients.JHLT open · 2025Article
- Lung Transplantation—Indications, Follow-Up Care and Long-Term Results.Deutsches Arzteblatt international · 2025Review
- Artificial intelligence and machine learning in cell-free-DNA-based diagnostics.Genome research · 2025Review
- Diagnostic approach to elevated dd-cfDNA with reassuring EMB in heart transplantation.Frontiers in transplantation · 2025Review
- Donor-derived cell-free DNA for detection of acute rejection in lung transplant recipients.Frontiers in immunology · 2025Article
- History of Heart Transplant: Setting the Stage.Methodist DeBakey cardiovascular journal · 2025Review
- Biomarkers for primary graft dysfunction after lung transplantation: a review of current evidence and future prospects.Frontiers in physiology · 2025Review
- Longitudinal Assessment of T1 Mapping Trends Disease in Pediatric Patients With Heart Transplant.Journal of the American Heart Association · 2024Article
- Clinical utility of plasma percent donor-derived cell-free DNA for lung allograft surveillance: A real-world single-center experience.JHLT open · 2024Article
- Donor-derived Cell-free DNA Evaluation in Pediatric Heart Transplant Recipients: A Single-center 12-mo Experience.Transplantation direct · 2024Article
- De Novo Donor-Specific Antibodies after Heart Transplantation: A Comprehensive Guide for Clinicians.Journal of clinical medicine · 2023Review
- Relative Change in Donor-Derived Cell-free DNA is Superior to Absolute Values for Diagnosis of Acute Lung Allograft Dysfunction.Transplantation direct · 2023Article
- Cardiac xenotransplantation: from concept to clinic.Cardiovascular research · 2023Review
- Single center study investigating the clinical association of donor-derived cell-free DNA with acute outcomes in lung transplantation.Frontiers in transplantation · 2023Article
- Cell-free DNA measurement of three genomes after allogeneic MSC therapy in kidney transplant recipients indicates early cell death of infused MSC.Frontiers in immunology · 2023Article
- Clinical relevance of cell-free DNA quantification and qualification during the first month after lung transplantation.Frontiers in immunology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewAcute allograft rejection is a common cause of morbidity and mortality in heart and lung transplantation. Unfortunately, the current monitoring gold standard-biopsy plus histopathology-has several limitations. Plasma donor-derived cell-free DNA (dd-cfDNA) has emerged as a potentially valuable biomarker for rejection that addresses some of the limitations of biopsy. This review covers the current state of the evidence and future directions for the use of dd-cfDNA in the monitoring of acute rejection. RECENT
findingsThe results of several observational cohort studies demonstrate that levels of dd-cfDNA increase in the setting of acute cellular rejection and antibody-mediated rejection in both heart and lung transplant recipients. dd-cfDNA demonstrates acceptable performance characteristics, but low specificity for the detection of underlying injury from rejection or infection. In particular, the high negative predictive value of the test in both heart and lung transplant patients provides the potential for its use as a screening tool for the monitoring of allograft health rather than tissue biopsy alone. SUMMARY: Existing evidence shows that dd-cfDNA is a safe, convenient, and reliable method of acute rejection monitoring in heart and lung transplant recipients. Further studies are required to validate threshold values for clinical use and determine its role in the diagnosis of alternative forms of allograft injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.